滨化集团股份有限公司 募集资金专项存储及使用管理制度 第一章 总则 第一条 为了规范公司募集资金的使用与管理，最大程度地保障投资者的利 益，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证 券法》（以下简称《证券法》）、中国证券监督管理委员会《上市公司募集资金监 管规则》《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指 引第 1 号——规范运作》以及其他相关法律、法规和规范性文件的规定，结合公 司实际情况，特制定本管理制度。 第二条 本管理制度所指募集资金是指公司通过向不特定对象发行证券(包 括首次发行股票、配股、增发、发行可转换公司债券、发行分离交易的可转换公 司债券等)以及向特定对象发行证券募集的资金，但不包括公司实施股权激励计 划募集的资金。 第三条 募集资金到位后，公司应及时办理验资手续，由具有证券从业资格 的会计师事务所出具验资报告，并应立即按照募股说明书所承诺的募集资金使用 计划，组织募集资金的使用工作。 第四条 募集资金只能用于公司对外公布的募集资金投向的项目。公司董事 会应制定详细的资金使用计划，做到资金使用的规范、公开和透明。 第五条 公司董事会应根据法 ...

Group 1 - The core viewpoint of the news is that Binhua Co., Ltd. has seen a stock price increase of 1.17%, reaching 4.33 yuan per share, with a total market capitalization of 8.906 billion yuan [1] - Binhua Co., Ltd. is located in Shandong Province and was established on May 21, 1998, with its listing date on February 23, 2010. The company specializes in the production, processing, and sales of organic and inorganic chemical products [1] - The main business revenue composition of Binhua Co., Ltd. includes: Other 56.57%, Propylene Oxide 22.48%, Caustic Soda 15.12%, and Propylene 5.83% [1] Group 2 - Among the top ten circulating shareholders of Binhua Co., Ltd., a fund under Southern Fund holds a significant position. The Southern CSI 1000 ETF (512100) reduced its holdings by 185,500 shares in the third quarter, now holding 18.806 million shares, which is 0.93% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 76.63 billion yuan. Year-to-date returns are 29.2%, ranking 1850 out of 4195 in its category; the one-year return is 24.73%, ranking 2053 out of 4179; and since inception, the return is 14.34% [2]

Group 1 - The National Venture Capital Guidance Fund has officially launched, focusing on early-stage investments in sectors such as integrated circuits, artificial intelligence, aerospace, and low-altitude economy [1][3] - The fund aims to mobilize nearly 1 trillion yuan in local and social capital through its establishment [3] - Three regional sub-funds have been established in Beijing, Shanghai, and Shenzhen, with total scales of 296.46 billion yuan, 471 billion yuan, and 450.5 billion yuan respectively [3] Group 2 - The fund features a three-tier structure: national mother fund, regional mother funds, and sub-funds, with a 20-year duration to promote "patient capital" [4] - Sub-funds are required to invest 70% of their capital in seed and early-stage projects, without regional reinvestment obligations [4] - The private equity and venture capital market is expected to see a significant increase, with a 37.42% year-on-year growth in new registered funds by Q3 2025 [4] Group 3 - State-owned capital dominates the LP market with an investment of 123.12 billion yuan, accounting for 46.8% of total contributions [5] - Corporate investors contribute 44.15 billion yuan, representing 16.8% of the total, primarily from industrial groups and listed companies [5] - Nearly 300 listed companies have engaged in or are planning to establish investment funds this year [5] Group 4 - Companies like Meinian Health and Binhua Co. are actively participating in venture capital by establishing or investing in funds focused on AI, automation, and strategic emerging industries [6][7] - The investment strategies of these companies aim to enhance their competitive edge and align with their long-term strategic goals [6][7] - The establishment of investment funds by listed companies is seen as a way to expand business opportunities and leverage professional investment capabilities [9]

Group 1 - Guangqi Technology's controlling shareholder proposed a share buyback of 50 million to 100 million yuan for employee stock ownership plans or equity incentives [1] - Xingyuan Zhuomai received a supplier designation from a domestic electric vehicle manufacturer to develop and supply reducer shell components, with expected sales of approximately 575 million yuan over four years from 2027 to 2030 [2] - Weigao Bio's application for clinical trials of subcutaneous human immunoglobulin has been accepted by the National Medical Products Administration, targeting primary immunodeficiency diseases [3] Group 2 - Hongda Electronics disclosed uncertainty regarding the IPO progress of its associate Jiangsu Zhanxin, in which it holds a 13.79% stake [4] - Kangchen Pharmaceutical received FDA approval to conduct clinical trials for its KC1086 project, aimed at treating advanced recurrent or metastatic solid tumors [5] - Kweichow Moutai adjusted its share buyback price ceiling to 1863.67 yuan per share, effective from December 19, 2025 [6] Group 3 - Mousse Co. announced that its controlling shareholder and actual controllers committed not to reduce their holdings within one year [7] - Tongxingbao's subsidiary signed a business contract worth 43.166 million yuan for a cloud expansion project [8] - Kaifa Electric announced plans for three shareholders to collectively reduce their holdings by 0.6999% [9] Group 4 - Longpan Technology plans to increase the production capacity of lithium iron phosphate cathode materials from 62,500 tons per year to 100,000 tons per year [10] - Zhuhai Guanyu announced plans for two shareholders to reduce their holdings by up to 3% [11] - Jiaheng Home Textiles is planning a change in control, leading to a temporary suspension of its stock [12] Group 5 - Kehua Bio's subsidiary received a medical device registration certificate for a gene polymorphism detection kit [13] - Saitex New Materials' actual controller plans to reduce holdings by up to 3% [14] - Sanhui Electric announced a shareholder's plan to reduce holdings by up to 2% [15] Group 6 - Binhua Co. plans to establish a venture capital fund with a total scale of 400 million yuan, focusing on strategic emerging industries [16] - Jindun Co. announced plans for two shareholders to reduce their holdings by up to 4% [17] - Hengdian East Magnetic's controlling shareholder plans to reduce holdings by up to 1% [18][19] Group 7 - Luxin Investment's controlling shareholder plans to reduce holdings by up to 1% [20] - Huakang Clean announced a joint bid for a hospital procurement project worth 157 million yuan [21] - Xuedilong plans to reduce its repurchased shares by up to 488,560 shares [22] Group 8 - Enhua Pharmaceutical's subsidiary signed an exclusive commercial cooperation agreement for three long-acting antipsychotic products [23] - Aier Eye Hospital plans to acquire partial equity in 39 institutions for a total of 963 million yuan [24] - Gaozheng Mining plans to acquire 100% equity of Overseas Explosives for 510 million yuan [25] Group 9 - Donghong Co. plans to repurchase shares worth 30 million to 60 million yuan for employee stock ownership plans [26] - Bear Electric's controlling shareholder plans to reduce holdings by up to 0.64% [27] - *ST Zhengping announced the initiation of pre-restructuring by the Xining Intermediate Court [28][29] Group 10 - Caesar Travel's shareholder plans to reduce holdings by up to 3% [30] - Lianchuang Electronics announced a change in controlling shareholder to Jiangxi State-owned Assets Supervision and Administration Commission [31] - Beixin Road and Bridge plans to transfer 5.33% equity in Henan Yuhang for 243 million yuan [32] Group 11 - Fenglong Co. is planning a change in control, with stock resuming trading [33]

Group 1 - The core viewpoint of the news is that Binhua Co., Ltd. is strategically investing in emerging industries by establishing a partnership with investment institutions to create a sustainable industrial ecosystem [1][2] - The total scale of the targeted fund is 400 million yuan, with Binhua Co., Ltd. contributing 199 million yuan as a limited partner and its subsidiary contributing 1 million yuan as a general partner [1] - The fund will focus on strategic emerging industries such as synthetic biology, new energy, new materials, special chemicals, energy conservation and environmental protection, and high-end equipment manufacturing [1] Group 2 - Binhua Co., Ltd. aims to implement its "technology-driven" strategy through collaboration with professional investment institutions, which will not lead to competition or affect the company's normal operations [2] - The company reported a revenue of 11.148 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 47.35%, while the net profit attributable to shareholders was 192 million yuan, up 1.63% year-on-year [3] - The company has a strong production capacity in the chemical sector, with 610,000 tons of caustic soda and 510,000 tons of propylene oxide, ranking among the top in Shandong province [2][3]

Core Viewpoint - The company is advancing its "technology-driven" strategy by establishing a partnership to invest in emerging industries, focusing on sustainable development and cutting-edge technologies [1] Group 1: Investment Details - The company and its subsidiary, Hengqin Changyue, signed a partnership agreement with Guotou Guofu Fund Management Co., Ltd. and Guotou Investment Management Group Co., Ltd. on December 23, 2025 [1] - The total scale of the targeted fund is RMB 400 million, with the company committing RMB 199 million as a limited partner and Hengqin Changyue contributing RMB 1 million as a general partner [1] - Guotou Investment Management Group is also a limited partner contributing RMB 199 million, while Guotou Guofu Fund acts as the fund manager and general partner, contributing RMB 1 million [1] Group 2: Focus Areas - The targeted fund will primarily invest in strategic emerging industries, including synthetic biology, new energy, new materials, specialty chemicals, energy conservation and environmental protection, and high-end equipment manufacturing [1]

Core Viewpoint - The company, Binhua Co., Ltd. (601678.SH), has signed a partnership agreement for a new investment fund focused on strategic emerging industries, indicating a commitment to growth in sectors such as synthetic biology and new energy [1] Group 1: Investment Details - The total scale of the targeted fund is 400 million yuan, with the company contributing 199 million yuan as a limited partner [1] - The subsidiary, Hengqin Changyue, will act as the general partner and will contribute 1 million yuan [1] - Guotou Guofu Fund and Guotou Investment Management Group will also participate, each contributing 199 million yuan and 1 million yuan respectively [1] Group 2: Focus Areas of the Fund - The fund will primarily invest in strategic emerging industries, including synthetic biology, new energy, new materials, special chemicals, energy conservation and environmental protection, and high-end equipment manufacturing [1]

Group 1 - The company, Binhu Chemical (601678.SH), announced a partnership with its subsidiary, Hengqin Changyue, to establish a venture capital fund with a total scale of 400 million yuan [1] - The company will contribute 199 million yuan as a limited partner, while Hengqin Changyue will invest 1 million yuan as a general partner [1] - The fund will focus on strategic emerging industries such as synthetic biology, new energy, new materials, specialty chemicals, energy conservation and environmental protection, and high-end equipment manufacturing [1]

滨化集团股份有限公司 关于与专业投资机构共同设立创业投资基金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资标的名称：滨州北鲲领航创业投资基金合伙企业（有限合伙）（暂 定名，以市场监督管理部门最终登记核准的名称为准）（以下简称"合伙企业"、 "标的基金"） 证券代码：601678 证券简称：滨化股份 公告编号：2025-089 出资金额：标的基金规模人民币 4 亿元。其中，滨化集团股份有限公司 （以下简称"公司"）作为有限合伙人以自有资金认缴出资 1.99 亿元，公司子 公司广东省横琴长悦管理咨询有限公司（以下简称"子公司"、"横琴长悦"） 作为普通合伙人/执行事务合伙人以自有资金认缴出资 100 万元。 本次交易不构成同业竞争或关联交易，不构成重大资产重组。 本次投资未达到公司董事会和股东会审议标准。 风险提示：截至本公告日，标的基金尚处于设立过程中，尚未完成工商 登记和中国证券投资基金业协会备案，具体实施情况和进度存在不确定性。基 金具有投资周期长、流动性较低等特点，投资过程中会受到产业政策、经 ...

Core Viewpoint - The company, Binhua Co., Ltd. (滨化股份), has announced the establishment of a new investment fund focusing on strategic emerging industries, with a total fund size of 400 million yuan [1] Group 1: Fund Details - The newly established fund, named Binhai Beikun Pioneer Venture Capital Fund Partnership (Limited Partnership), has a total scale of 400 million yuan [1] - The company will contribute 199 million yuan as a limited partner, while its subsidiary, Hengqin Changyue, will contribute 1 million yuan as a general partner [1] Group 2: Investment Focus - The fund will primarily invest in sub-funds or projects within strategic emerging industries, including synthetic biology, new energy, new materials, specialty chemicals, energy conservation and environmental protection, and high-end equipment manufacturing [1]